FDCP
RGNX icon

Foster Dykema Cabot & Partners’s Regenxbio RGNX Stock Holding History

Foster Dykema Cabot & Partners’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,946
Closed -$18.8K – 410
2025
Q3 		$18.8K Buy
+1,946
New +$17.2K ﹤0.01% 308

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Foster Dykema Cabot & Partners's RGNX Position: Q4 2025 in Review

Foster Dykema Cabot & Partners sold out of Regenxbio (RGNX) in Q4 2025, closing a stake of 1,946 shares — an estimated $18.8K sold.

Foster Dykema Cabot & Partners first reported a position in RGNX in Q3 2025 and held it in 1 quarter. The position peaked at $18.8K in Q3 2025. 174 funds tracked by Wall St. Rank hold RGNX as of Q4 2025.

  • Foster Dykema Cabot & Partners reported no remaining Regenxbio position as of Q4 2025 after selling out during the quarter.
  • Foster Dykema Cabot & Partners sold 1,946 Regenxbio shares in Q4 2025, an estimated $18.8K.
  • Foster Dykema Cabot & Partners first reported a position in Regenxbio in Q3 2025 and held it in 1 quarter.
  • Foster Dykema Cabot & Partners's Regenxbio position peaked at $18.8K in Q3 2025.
  • 174 funds tracked by Wall St. Rank held Regenxbio as of Q4 2025.

Based on Foster Dykema Cabot & Partners's 13F filing for Q4 2025, filed 12 Feb 2026.